Two poster presentations at the ESMO Meeting Lugano this complete week display that the drug.

Ten of these men have seen PSA declines greater than 50 percent which have lasted at least three months right away of taking abiraterone, without major toxicities or adverse events. Overall, the results are significant, the authors say. The drug has produced PSA decline prices by greater than 50 percent in 60 percent of pre-docetaxel individuals and 50 percent of post-docetaxel patients. These results are supported by evidence of tumour shrinkage on scans, drops in circulating tumor cell improvements and counts in symptoms. Related StoriesNew results reveal association between colorectal cancers and melanoma drug treatmentMeat-rich diet may boost kidney cancer riskCrucial transformation in single DNA bottom predisposes children to intense form of cancerA Phase III trial of abiraterone is planned for next year.All eligible participants will be randomly designated to take either a low dose aspirin or a placebo daily for about five years. Participants will receive preliminary measurements on specific health markers, along with functional and cognitive ability, and changes in these will be monitored through the entire study. ‘The outcomes from the ASPREE research can help healthy older people work with their doctors to make more informed decisions about whether aspirin ought to be used to increase life without disability,’ states Dr.